Doctor D. Schwab recalled 810 tubes of Clinical Weh Weh Natural Pain Relief Gel on October 10, 2025. The recall stems from CGMP deviations that could compromise product safety. The affected product was distributed in California, Colorado, Florida, Puerto Rico, and Washington.
CGMP Deviations
Consumers and healthcare providers should stop using this product immediately. Contact CA BOTANA International, Inc. or your healthcare provider for guidance. Notification method: Letter
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The recalled product, Doctor D. Schwab Clinical Weh Weh Natural Pain Relief Gel, contains 5% menthol and 4.2 oz. per tube. It is identified by NDC: 35192-020-02 and was sold in various states including CA, CO, FL, PR, and WA.
The recall is due to deviations from Current Good Manufacturing Practices (CGMP). These deviations can result in quality issues, potentially leading to compromised safety for consumers.
There are no reported injuries or incidents associated with this recall. Despite the lack of reported harm, the high hazard level indicates potential risks.
Consumers should stop using the recalled product immediately. Contact CA BOTANA International, Inc. or consult a healthcare provider for further guidance.
For more information, consumers can visit the FDA website or contact CA BOTANA International, Inc. directly.
Get instant alerts for recalls that affect you. Free forever.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.
Fresenius Kabi Compounding recalled 1,578 bags of vancomycin HCl injection on February 5, 2026. The company cited a lack of assurance of sterility as the reason for the recall. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,410 bags of ketamine HCl injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers and consumers must stop using this product immediately.
Fresenius Kabi Compounding recalled 10,548 bags of thiamine HCl injection on February 5, 2026. The recall follows a lack of assurance of sterility, posing a high health risk. Affected products include several lots expiring between February and May 2026.
Pro Numb Tattoo Numbing Spray was recalled due to cGMP deviations. The recall affects products distributed nationwide in the USA. Consumers should stop using the spray immediately and contact Pro Numb Tattoo Numbing Spray LLC for guidance.
Pro Numb Tattoo Numbing Spray was recalled on February 2, 2026 due to cGMP deviations. The product, containing 4% lidocaine, is distributed by Pro Numb Tattoo Numbing Spray LLC. Consumers should stop using it immediately and contact the company for further guidance.